CA2189067A1 - Vecteur d'apport de genes utilisant un adn plasmidique encapsule dans un adenovirus et une lignee cellulaire d'encapsidation - Google Patents

Vecteur d'apport de genes utilisant un adn plasmidique encapsule dans un adenovirus et une lignee cellulaire d'encapsidation

Info

Publication number
CA2189067A1
CA2189067A1 CA 2189067 CA2189067A CA2189067A1 CA 2189067 A1 CA2189067 A1 CA 2189067A1 CA 2189067 CA2189067 CA 2189067 CA 2189067 A CA2189067 A CA 2189067A CA 2189067 A1 CA2189067 A1 CA 2189067A1
Authority
CA
Canada
Prior art keywords
adenovirus
dna
pseudo
expression vector
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2189067
Other languages
English (en)
Inventor
Gary J. Nabel
Michael J. Imperiale
Takeshi Ohno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan Ann Arbor
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2189067A1 publication Critical patent/CA2189067A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 2189067 1994-04-28 1995-04-25 Vecteur d'apport de genes utilisant un adn plasmidique encapsule dans un adenovirus et une lignee cellulaire d'encapsidation Abandoned CA2189067A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23499094A 1994-04-28 1994-04-28
US08/234,990 1994-04-28

Publications (1)

Publication Number Publication Date
CA2189067A1 true CA2189067A1 (fr) 1995-11-09

Family

ID=22883604

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2189067 Abandoned CA2189067A1 (fr) 1994-04-28 1995-04-25 Vecteur d'apport de genes utilisant un adn plasmidique encapsule dans un adenovirus et une lignee cellulaire d'encapsidation

Country Status (4)

Country Link
EP (1) EP0763103A4 (fr)
JP (1) JPH10507061A (fr)
CA (1) CA2189067A1 (fr)
WO (1) WO1995029993A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
DE69534166T2 (de) * 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
AU5551996A (en) * 1995-04-17 1996-11-07 Board Of Regents, The University Of Texas System An adenovirus helper-virus system
DE69733815T2 (de) 1996-02-15 2006-06-08 Biosense Webster, Inc., Diamond Bar Sonde zur exkavation
AU2319497A (en) * 1996-03-07 1997-09-22 Regents Of The University Of California, The Helper-free, totally defective adenovirus for gene therapy
US6443974B1 (en) 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
CA2671261A1 (fr) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Antigenes de neisseria
JP2002507384A (ja) * 1997-11-25 2002-03-12 プリンストン ユニヴァーシティー アデノウイルスベクターの製造方法、それによって製造したベクターおよびその使用
NZ505325A (en) 1997-12-23 2003-07-25 Crucell Holland B Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells
EP1047784B2 (fr) 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Antigenes du neisseria meningitidis
ES2255155T3 (es) 1998-02-05 2006-06-16 Biosense Webster, Inc. Dispositivo para la administracion intracardiaca de farmacos.
EP2261338A3 (fr) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
GB9817660D0 (en) 1998-08-13 1998-10-07 Angeletti P Ist Richerche Bio Adenoviral vectors encoding erythropoietin and their use in gene therapy
WO2000066741A2 (fr) 1999-04-30 2000-11-09 Chiron S.P.A. Antigenes de neisseria conserves
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
JP2004508801A (ja) 1999-10-29 2004-03-25 カイロン　ソチエタ　ア　レスポンサビリタ　リミタータ ナイセリア抗原性ペプチド
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
CA2881568C (fr) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Acides nucleiques et proteines derives des groupes de streptocoques a et b
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
RU2331435C2 (ru) 2001-12-12 2008-08-20 Чирон Срл. Иммунизация против chlamydia trachomatis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
JP4792390B2 (ja) 2004-03-29 2011-10-12 株式会社ガルファーマ 新規ガレクチン９改変体タンパク質及びその用途
PT2229956E (pt) 2004-09-13 2013-07-31 Genzyme Corp Contruções multiméricas
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
HUE040490T2 (hu) 2006-02-09 2019-03-28 Genzyme Corp Lassú intraventrikuláris szállítás
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
JP6188728B2 (ja) 2012-02-07 2017-08-30 グローバル・バイオ・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｉｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 核酸送達の区画化方法ならびにその組成物および使用
HK1225258B (en) 2013-08-08 2017-09-08 Global Bio Therapeutics, Inc. Clamping device for minimally invasive surgery
US20240366681A1 (en) 2021-08-13 2024-11-07 Triovance Holding Llc A skin substitute composition and methods of producing and using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233013T2 (de) * 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
ATE404683T1 (de) * 1992-09-25 2008-08-15 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.

Also Published As

Publication number Publication date
EP0763103A4 (fr) 1998-07-15
WO1995029993A1 (fr) 1995-11-09
EP0763103A1 (fr) 1997-03-19
JPH10507061A (ja) 1998-07-14

Similar Documents

Publication Publication Date Title
CA2189067A1 (fr) Vecteur d'apport de genes utilisant un adn plasmidique encapsule dans un adenovirus et une lignee cellulaire d'encapsidation
US20230272349A1 (en) Tumor-selective e1a and e1b mutants
DE69433461T2 (de) Rekombinanter Alphavirus Vektor
EP1032696B1 (fr) Vecteur pour replication et expression genique a specificite tissulaire
AU716045B2 (en) Vectors for tissue-specific replication
US6156497A (en) Recombinase-mediated generation of adenoviral vectors
US5998205A (en) Vectors for tissue-specific replication
WO1996017053A9 (fr) Vecteurs de replication a specificite tissulaire
IL112860A (en) Defective recombinant adenoviral vectors, their preparation and their therapeutic uses
JPH11508770A (ja) 組織特異的ウイルスベクター
WO1997025446A9 (fr) Generation de vecteurs adenoviraux a mediation de recombinase
JP2012080889A (ja) 多コンパートメント真核生物発現系
JP4386971B2 (ja) スプライシング配列を含んでなる組換えアデノウイルスベクター
JP2001502883A (ja) ミニアデノウイルスベクター
AU717218B2 (en) Medicinal combination useful for in vivo exogenic transfection and expression
Murphy et al. Cloning vectors for expression of cDNA libraries in mammalian cells.
DE69527544T2 (de) Kombinationsvektoren zum austragen von genmaterial
KR100246096B1 (ko) 유전자 요법을 위한 개선된 레트로바이러스 벡터
JP2002330786A (ja) 抗炎症性ベクター
US20020019051A1 (en) Chimeric adenoviral vectors
JPH10506018A (ja) 不活化ＩＶａ２遺伝子を有する欠陥組換えアデノウィルス
JP2001500021A (ja) 新規な内部リボソームエントリー部位およびそれを含有するベクター
Brady et al. Map of cis-acting sequences that determine alternative pre-mRNA processing in the E3 complex transcription unit of adenovirus
WO2002008436A2 (fr) Système de vecteur mini-adénoviral pour vaccination
AU747831B2 (en) DNA virus vectors and methods for their preparation

Legal Events

Date Code Title Description
FZDE Dead